Tsilimbaris Miltiadis K, Pandeleondidis Vassilios, Panagiototglou Theoni, Arvanitaki Vassiliki, Fragiskou Sofia, Eleftheriadou Maria, Tsika Chrysanthi, Papadaki Theokliti
Retina Service, University Eye Clinic of Heraklion, Crete, Greece.
Semin Ophthalmol. 2009 Nov-Dec;24(6):225-30. doi: 10.3109/08820530903389775.
To evaluate the effect of intravitreal injection of the combination of Triamcinolone Acetonide and Bevacizumab in patients with diabetic macular edema.
Twenty seven eyes of 17 patients with diabetic macular edema were treated with an intravitreal injection of triamcinolone acetonide (2 mg) combined with bevacizumab (1.25 mg).
During the 6 months follow-up period 24 eyes (89%) had to repeat the treatment according to the monthly follow-up examination.The mean visual acuity and the central macular thickness improved significantly (P<0.05) throughout the follow-up period.
Intravitreal combination of Triamcinolone Acetonide and Bevacizumab seems to be effective in improving visual acuity and macular edema in patients with diabetic maculopathy.
评估玻璃体内注射曲安奈德和贝伐单抗联合用药对糖尿病性黄斑水肿患者的疗效。
17例糖尿病性黄斑水肿患者的27只眼接受了玻璃体内注射曲安奈德（2毫克）联合贝伐单抗（1.25毫克）的治疗。
在6个月的随访期内，根据每月的随访检查，24只眼（89%）需要重复治疗。在整个随访期内，平均视力和中心黄斑厚度均有显著改善（P<0.05）。
玻璃体内注射曲安奈德和贝伐单抗联合用药似乎对改善糖尿病性黄斑病变患者的视力和黄斑水肿有效。
